


## Fobrepodacin

Cat. No.:	HY-135655A
CAS No.:	1384984-31-9
Molecular Formula:	C <sub>21</sub> H <sub>26</sub> FN <sub>6</sub> O <sub>6</sub> P
Molecular Weight:	508.44
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Fobrepodacin (SPR720) is an orally active and potent phosphate proagent of SPR719 (VXc-486; HY-12930). Fobrepodacin has potent bactericidal activities in vivo <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Fobrepodacin (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice<sup>[1]</sup>.</p> <p>Fobrepodacin (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10, 30, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; once per day; 5 times per week for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.</td> </tr> </table>	Animal Model:	Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman) <sup>[1]</sup>	Dosage:	10, 30, 100 mg/kg	Administration:	Oral gavage; once per day; 5 times per week for 4 weeks	Result:	Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.
Animal Model:	Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman) <sup>[1]</sup>								
Dosage:	10, 30, 100 mg/kg								
Administration:	Oral gavage; once per day; 5 times per week for 4 weeks								
Result:	Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.								

### REFERENCES

[1]. Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. *Antimicrob Agents Chemother.* 2015 Mar;59(3):1455-65.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA